EUCTR2009-011925-14-HU进行中（未招募）1 期
A multicentre, open label, phase I/randomised phase II study to evaluatesafety, pharmacokinetics and efficacy of BIBF 1120 in comparison withSorafenib for advanced hepatocellular carcinoma patients
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 132
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. HCC, either histologically/cytologically confirmed diagnosis or clinically diagnosis by
- •AASLD criteria, which is not amenable to local therapy (RFA, PEI, RT, TACE)
- •2. Age 18 years or older
- •3. ECOG performance score of 2 or less
- •4. Child-Pugh score of 7 or less
- •5. At least one measurable lesion according to RECIST 1.0 (this criterion is limited to
- •phase II only)
- •6. Measurable lesion previously treated by local therapy (RFA, PEI, RT, TACE) must
- •have documented progression according to RECIST 1.0 by CT or MRI (this criterion
- •is limited to phase II only)
- •7. Time interval from last local therapy more than 4 weeks prior to start of study
- •8. Written informed consent consistent with ICH-GCP and local legislation
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Prior systemic therapy for metastatic/unresectable HCC (for phase II)
- •2. More then one line of prior systemic therapy for metastatic/unresectable HCC (for
- •3. Fibrolamellar HCC
- •4. Uncontrolled or refractory ascites by adequate medical therapy
- •5. Bilirubin greater than 1.5 times ULN
- •6. AST or ALT greater than 5 times ULN
- •7. Hepatic encephalopathy more than grade 1 according to Child-Pugh criteria
- •8. Prothrombin time international normalized ratio greater than 2.3, or prothrombin
- •time more than 6 seconds prolonged than control
- •9. Absolute neutrophil count less than 1000/µL
- •10. Platelet count less than 60000/µL
- •11. Hemoglobin less than 9 g/dL
- •12. Serum creatinine greater than 1.5 times ULN
- •13. Proteinuria of CTCAE grade 2 or greater
- •14. Variceal bleeding within 6 months prior to start of study treatment
- •15. History of major thrombotic (except portal vein thrombosis) or clinically relevant
- •major bleeding event in the past 6 months
- •16. Known inherited predisposition to bleeding or thrombosis
- •17. Significant cardiovascular diseases (i.e. hypertension not controlled by medical
- •therapy (blood pressure > 150/90 mmHg), unstable angina, history of myocardial
- •infarction within the past 6 months, congestive heart failure > NYHA II, serious
- •cardiac arrhythmia, pericardial effusion)
- •18. Therapeutic anticoagulation (except low dose heparin and/or heparin flush as
- •needed for maintenance of an indwelling intravenous device) or antiplatelet
- •therapy (except for chronic low-dose therapy with acetylsalicylic acid = 325mg
- •19. Last administration of systemic treatment for HCC within 4 weeks prior to start
- •of study treatment or no recovery from any treatment related toxicity
- •20. Major surgery within 4 weeks prior to start of study treatment
- •21. Treatment with other investigational drugs concomitantly with this trial (except
- •for present trial drug)
- •22. Serious illness or concomitant non-oncological disease such as neurologic,
- •psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or
- •laboratory abnormality that may increase the risk associated with study
- •participation or study drug administration and in the judgment of the
- •investigator would make the patient inappropriate for entry into the study
- •23. Patients who are sexually active and unwilling to use a medically acceptable
- •method of contraception (e.g. such as implants, injectables, combined oral
- •contraceptives, some intrauterine devices or vasectomized partner for
- •participating females, condomes for participating males) during the trial and for
- •at least twelve months after end of active therapy
- •24. Current alcohol abuse or drug abuse that would limit patient ability to comply
- •with protocol
- •25. Symptomatic CNS metastasis
- •26. Life expectancy less than 12 weeks
- •27. Patient unable to take oral medication
- •28. Gastrointestinal disorders or abnormalities that would interfere with absorption
- •of the study drug
- •29. Pregnancy or breast feeding
- •30. Patient unable to comply with the protocol
- •31. Other malignancy within the past three years other than basal cell skin cancer,
- 另有 3 项未显示
研究者
相似试验
进行中（未招募）
1 期
Phase I/II comparison of efficacy and safety of BIBF 1120 and sorafenib in patients with advanced hepatocellular carcinomaHistologically or cytologically confirmed hepatocellular carcinoma not amenable to local therapy with adequate renal, hematological and liver paramenters with Child-Pugh score 7 or less, in 1st line systemic therapy.MedDRA version: 14.0Level: LLTClassification code 10049010Term: Carcinoma hepatocellularSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-011925-14-SKBoehringer Ingelheim RCV GmbH & Co KG132
进行中（未招募）
1 期
Study investigating safety and efficacy of PQR309 and eribulin combination in patients with locally advanced or metastatic HER2 negative and triple-negative breast cancerEUCTR2015-004225-14-GBPIQUR Therapeutics AG31
进行中（未招募）
1 期
Study investigating safety and efficacy of PQR309 and eribulin combination in patients with locally advanced or metastatic HER2 negative and triple-negative breast cancerEUCTR2015-004225-14-ESPIQUR Therapeutics AG31
进行中（未招募）
不适用
An open label, multicenter, non randomized phase II study to evaluate anti-tumor efficacy and safety of GM-CSF (sargramostim, Leukine®) associated with Rituximab (MabThera®) in patients with follicular non Hodgkin’s lymphoma with no prior treatment - FL2008 RGMEUCTR2007-005580-95-FRGoelams
进行中（未招募）
不适用
An open label, multicenter, non randomized phase II study to evaluate anti-tumor efficacy and safety of GM-CSF (sargramostim, Leukine®) associated with RCHOP chemotherapy and Rituximab (MabThera®) maintenance in patients with first-line advanced follicular non Hodgkin’s lymphoma - FL2008 RCHOPGMThis study evaluate anti-tumor efficacy and safety of GM-CSF (sargramostim, Leukine®) associated with Rituximab (MabThera®) and chemotherapy (CHOP) in patients with non bulky follicular non Hodgkin’s lymphoma with no prior treatment.MedDRA version: 9.1Level: LLTClassification code 10025310Term: LymphomaEUCTR2007-007056-33-FRGoelams